A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.

Cancer patients are set to receive, for the first time, a highly innovative investigational drug called NXP800 – which was discovered at The Institute of Cancer Research, London.

A new drug designed to counter the effects of an important, but very hard to target, cancer mutation could be effective against a range of tumour types including lung and gynaecological cancers, a new clinical trial shows.